HK1222569A1 - 用於誘導免疫反應的糖疫苗組合物及其治療癌症的用途 - Google Patents

用於誘導免疫反應的糖疫苗組合物及其治療癌症的用途

Info

Publication number
HK1222569A1
HK1222569A1 HK16110810.9A HK16110810A HK1222569A1 HK 1222569 A1 HK1222569 A1 HK 1222569A1 HK 16110810 A HK16110810 A HK 16110810A HK 1222569 A1 HK1222569 A1 HK 1222569A1
Authority
HK
Hong Kong
Prior art keywords
compositions
immune responses
cancer treatment
inducing immune
carbohydrate vaccine
Prior art date
Application number
HK16110810.9A
Other languages
English (en)
Inventor
Cheng-Der Tony Yu
Cheng-Chi Irene Wang
Wei-Han Lee
Yu-Chen Lin
Yu-Hsin Tom Lin
I-Ju Chen
Original Assignee
Obi Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Pharma Inc filed Critical Obi Pharma Inc
Publication of HK1222569A1 publication Critical patent/HK1222569A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001173—Globo-H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HK16110810.9A 2013-09-17 2016-09-13 用於誘導免疫反應的糖疫苗組合物及其治療癌症的用途 HK1222569A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361878982P 2013-09-17 2013-09-17
PCT/IB2014/002744 WO2015159118A2 (en) 2013-09-17 2014-09-15 Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment

Publications (1)

Publication Number Publication Date
HK1222569A1 true HK1222569A1 (zh) 2017-07-07

Family

ID=53935288

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16109563.0A HK1221476A1 (zh) 2013-09-17 2016-08-10 用於誘導免疫反應的糖疫苗組合物及其治療癌症的用途
HK16110810.9A HK1222569A1 (zh) 2013-09-17 2016-09-13 用於誘導免疫反應的糖疫苗組合物及其治療癌症的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16109563.0A HK1221476A1 (zh) 2013-09-17 2016-08-10 用於誘導免疫反應的糖疫苗組合物及其治療癌症的用途

Country Status (19)

Country Link
US (1) US20150297696A1 (zh)
EP (1) EP3046588B1 (zh)
JP (1) JP6431920B2 (zh)
KR (1) KR20160055861A (zh)
CN (1) CN105764921B (zh)
AR (1) AR097661A1 (zh)
AU (2) AU2014391422A1 (zh)
BR (1) BR112015032713B1 (zh)
CA (1) CA2924286C (zh)
CL (1) CL2016000538A1 (zh)
ES (1) ES2914176T3 (zh)
HK (2) HK1221476A1 (zh)
IL (1) IL242907B (zh)
NZ (1) NZ714555A (zh)
PH (1) PH12015502629B1 (zh)
RU (1) RU2666141C2 (zh)
SG (1) SG11201510740YA (zh)
TW (1) TWI641383B (zh)
WO (1) WO2015159118A2 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456766B (zh) 2014-03-19 2020-03-10 台湾基督长老教会马偕医疗财团法人马偕纪念医院 抗免疫原性糖肽的抗体、包含其的组合物及其用途
CA2961522A1 (en) * 2014-09-15 2016-03-24 Obi Pharma, Inc. Immunogenic/therapeutic glycoconjugate compositions and uses thereof
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
CA3019560A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP3445395A4 (en) 2016-04-22 2019-12-25 OBI Pharma, Inc. ANTI-CANCER IMMUNOTHERAPY BY IMMUNO-ACTIVATION OR IMMUNOMODULATION THROUGH GLOBO SERIES ANTIGENS
KR20230117482A (ko) * 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
EP3491026A4 (en) 2016-07-29 2020-07-29 OBI Pharma, Inc. HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
WO2018054353A1 (en) * 2016-09-23 2018-03-29 Chang, Chih-Long Anti-globo h antibodies
BR112019010356A2 (pt) 2016-11-21 2019-08-27 Obi Pharma Inc molécula de carboidrato, conjugado fármaco-anticorpo (adc), composição, método para preparar a composição, método para tratar câncer em um indivíduo, método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo, composto conjugado de fármaco-anticorpo, uso de um composto conjungado anticorpo-fáramco, método para determinar a eficácia terapêutica de células de câncer ao adcc e método para fazer imagem de um indivíduo
WO2019232519A1 (en) * 2018-06-01 2019-12-05 Obi Pharma, Inc. Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibody
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
CN112924700A (zh) * 2021-01-26 2021-06-08 海南医学院 一种钥孔血蓝蛋白(KLH)的包被工艺及小鼠KLH特异性IgG抗体定量检测试剂盒
CN117377486A (zh) * 2021-05-24 2024-01-09 株式会社车疫苗研究所 采用包括脂肽和聚 (i∶c)的佐剂的免疫肿瘤学治疗组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU519567B2 (en) * 1977-07-13 1981-12-10 Akzo Nv Psychopharmacological penta and hexa-peptides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US6544952B1 (en) * 1994-03-15 2003-04-08 Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the globo-H epitope and uses thereof
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
EP1458242A4 (en) * 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER
WO2003015796A1 (en) * 2001-08-14 2003-02-27 Biomira, Inc. Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier
ATE475430T1 (de) * 2003-08-25 2010-08-15 Univax Llc Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) moleküls
RU2430110C2 (ru) * 2006-01-31 2011-09-27 Новартис Аг Антитела - антагонисты интерлейкина-17 (ил-17) для лечения рака
JPWO2009044918A1 (ja) * 2007-10-05 2011-02-17 武田薬品工業株式会社 ニューロメジンｕ誘導体
US20110117009A1 (en) * 2008-03-31 2011-05-19 Freie Universität Berlin Drug conjugates with polyglycerols
WO2011156774A2 (en) * 2010-06-11 2011-12-15 Sloan-Kettering Institute For Cancer Research Multivalent glycopeptide constructs and uses thereof
EP2500035A1 (en) * 2011-03-15 2012-09-19 Icon Genetics GmbH Pharmaceutical formulation containing immunglobulin
EP3228325A1 (en) * 2011-06-10 2017-10-11 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates

Also Published As

Publication number Publication date
CN105764921A (zh) 2016-07-13
PH12015502629A1 (en) 2016-03-07
RU2666141C2 (ru) 2018-09-06
EP3046588A2 (en) 2016-07-27
AU2019200314B2 (en) 2020-07-02
TWI641383B (zh) 2018-11-21
SG11201510740YA (en) 2016-01-28
BR112015032713A2 (pt) 2018-03-20
BR112015032713B1 (pt) 2023-03-21
PH12015502629B1 (en) 2016-03-07
AU2014391422A1 (en) 2015-12-17
JP6431920B2 (ja) 2018-11-28
WO2015159118A2 (en) 2015-10-22
WO2015159118A3 (en) 2016-03-17
ES2914176T3 (es) 2022-06-07
JP2016540099A (ja) 2016-12-22
EP3046588B1 (en) 2022-03-02
CA2924286C (en) 2022-06-21
CA2924286A1 (en) 2015-10-22
NZ714555A (en) 2020-03-27
AU2019200314A1 (en) 2019-02-07
EP3046588A4 (en) 2017-05-31
US20150297696A1 (en) 2015-10-22
TW201521766A (zh) 2015-06-16
AR097661A1 (es) 2016-04-06
CL2016000538A1 (es) 2016-10-28
CN105764921B (zh) 2020-06-30
KR20160055861A (ko) 2016-05-18
IL242907B (en) 2020-11-30
RU2015150769A (ru) 2017-10-23
HK1221476A1 (zh) 2017-06-02

Similar Documents

Publication Publication Date Title
HK1222569A1 (zh) 用於誘導免疫反應的糖疫苗組合物及其治療癌症的用途
HK1216991A1 (zh) 癌疫苗及使用其的治療方法
HK1218928A1 (zh) 癌症疫苗及接種方法
HK1222097A1 (zh) 用於吞嚥困難患者的營養的組合物
IL286759A (en) Therapeutic methods and preparations
HK1252695A1 (zh) 用於消除對治療劑的免疫應答的改進方法和化合物
ZA201508948B (en) Phenol derivative and preparation method and use in medicine thereof
IL251120B (en) Immunogenic/therapeutic glycoside preparations and their uses
HK1218880A1 (zh) 增强對艾美球蟲的免疫應答或限制艾美球蟲感染的組合物和方法
IL244354B (en) Flu vaccine and treatment
EP2956164A4 (en) OVARIAN CANCER VACCINES AND IMMUNIZATION METHODS
HK1248253A1 (zh) 對修飾的自體表位的抗腫瘤免疫應答
EP2892554A4 (en) HIV IMMUNOSTIMULATING COMPOSITIONS WITH RECOMBINANT EXPRESSED PILI ON BACTERIA AND CORRESPONDING METHODS
PL3129057T3 (pl) Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu
EP2934578A4 (en) VACCINES FOR TREATING CANCER AND COMPOSITIONS FOR IMPROVING VACCINE EFFICIENCY
EP3143036C0 (en) PAR-1 BASED THERAPEUTIC CONJUGATES AND USES THEREOF
HUE050547T2 (hu) Oligoszaccharid konjugátumok és alkalmazási eljárások
HK1216860A1 (zh) 單次高劑量的 在新生兒和嬰兒中誘導保護性免疫反應
EP2968398A4 (en) MODIFIED HYALURONAN AND USES THEREOF IN CANCER TREATMENT
GB201322958D0 (en) Uses of oligouronates in cancer treatment
GB201319255D0 (en) Therapeutic compositions and methods
GB201320958D0 (en) Improvements in and relating to medical devices
GB201309059D0 (en) Improvements in and relating to food shaping devices